The role of the neuropeptide galanin in the regulation of anterior pituitary function was studied in vivo in conscious male rats and in vitro with cultured anterior pituitary cells. injected into the third cerebral ventricle of rats produced highly significant, doserelated increases of plasma growth hormone (GH) concentrations, whereas galanin increased prolactin (PRL) and decreased thyroid-stimulating hormone (TSH) levels only at the highest dose (60 pmol) tested. Intravenous galanin failed to alter PRL and TSH levels in these rats. In contrast with the results with intraventricular injection of the peptide, intravenous injection of 30 or 300 pmol of galanin produced small, brief, dose-related increases in plasma GH. The response to the 300-pmol dose was less than that induced by a factor-of-20-lower intraventricular dose, which establishes a central action of galanin. Galanin in concentrations ranging from 1 nM to 1 gAM failed to alter significantly GH, PRL, or TSH release from dispersed anterior pituitary cells. It also failed to alter GH secretion in response to 100 nM GH-releasing hormone; however, at this dose galanin did potentiate the effect of 100 nM TSH-releasing hormone on TSH and PRL release. Thus, the effects ofthird-ventricular injection ofthe peptide are mediated by the hypothalamus. To determine the physiological significance of galanin in control of pituitary hormone release, highly specific antiserum against galanin was injected intraventricularly. Third-ventricular injection of 3 ,ul of galanin antiserum resulted in a dramatic decrease in plasma GH values as compared with those of normal rabbit serum-injected controls within 15 min, which persisted until the end of the experiment (5 hr postinjection). Galanin antiserum did not decrease plasma PRL or TSH levels at any time period after its third-ventricular injection; however, a transient increase of plasma TSH levels occurred after 30 and 60 min in comparison with TSH levels in normal rabbit serum-injected controls.
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Since there was no effect of the antiserum on plasma PRL and only a transient elevation in TSH, galanin may not be physiologically significant enough during resting conditions to alter PRL and TSH release in the male rat. The results of the experiments with galanin antiserum indicate that endogenous galanin has a tonic action within the hypothalamus to stimulate GH release. The rapidity of onset of the effects of galanin and the antiserum directed against it suggest that it acts to stimulate release of GH-releasing hormone from periventricular structures, which then stimulates the release of GH.
The gastrointestinal peptide galanin has been isolated from porcine intestinal extracts (1) . Galanin has been shown to cause contraction of smooth muscle preparations (1, 2) and to inhibit both substance P-and acetylcholine-induced smooth muscle contraction (2) . Furthermore, galanin causes hyperglycemia in dogs via inhibition of insulin release (1, 3) .
Galanin is widely distributed in the rat brain and intestine (4) (5) (6) (7) (8) . In the central nervous system, the hypothalamus is rich in fibers and cell bodies containing galanin-like immunoreactivity, with the highest concentration of galanin being found in the median eminence (6, 8) . Recently, receptors for galanin have been shown throughout the rat central nervous system (9, 10) . The presence of galanin-like immunoreactivity was established in the cholinergic neurons of the basal forebrain (9) . Coexistence of galanin-like immunoreactivity with catecholamines, 5-hydroxytryptamine, y-aminobutyric acid, and vasopressin has been reported in neurons (11, 12) .
The high-density network of galanin-like immunoreactive fibers in the hypothalamus is suggestive that there may be a neuroendocrine role for this peptide. We reported previously that injections of minute doses of galanin into the third ventricle (3V) caused an increase of plasma growth hormone (GH) levels in conscious rats (13) . Subsequently, much higher doses were reported to increase plasma prolactin (PRL) following lateral ventricular injection (14) .
In the present study, we have further examined the GH-stimulating activity of galanin in vivo by evaluating the effects of intravenous and 3V injections of the peptide on anterior pituitary hormone release in conscious, freely moving male-rats. We have also studied the effect of galanin on the release of pituitary hormones by dispersed pituitary cells in vitro. To examine the physiological significance of galanin in control of pituitary hormone secretion, we have evaluated the effects of 3V injections of highly specific antisera directed against galanin on the release of GH, PRL, and thyroidstimulating hormone (TSH).
EXPERIMENTAL PROCEDURES
Male rats (200-240 g) of the Sprague-Dawley strain were purchased from Sasco (Omaha, NE). Animals were maintained under controlled conditions (23-250C; lights on at time 0500 to 1900 and provided Rat Chow (British Petroleum, Saint Louis) and water ad libitum.
In Vivo Studies. Intravenous testing. Indwelling, right atrial cannulae were implanted via the external jugular vein; ether was the anesthetic (15) . Twenty-four hours later, individually caged, cannulated animals were moved to a quiet laboratory, and extension tubing (30.5-cm, PE-50 tubing, Clay Adams) was attached to the jugular cannula at its exit in the dorsum ofthe neck. Animals were then left undisturbed for 1 hr. After removal of the zero-time blood sample (0.6 ml), 0.2 ml of isotonic saline (0.9% NaCl) alone or saline containing 30 or Abbreviations: PRL, prolactin; TSH, thyroid-stimulating hormone; GH, growth hormone; TRH, TSH-releasing hormone; GRH, GHreleasing hormone; NRS, normal rabbit serum; 3V, third ventricle. *To whom reprint requests should be addressed.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 300 pmol of synthetic porcine galanin (Peninsula Laboratories, San Carlos, CA) was injected via the atrial cannula, followed by 0.4 ml of isotonic saline to replace the volume of blood withdrawn. Subsequent samplings (0.6 ml) at 5, 15, 30, and 60 min postinjection were followed by infusion of 0.6 ml of heparinized saline (20 units of heparin per ml). Blood samples were centrifuged at 4TC, and plasma was stored frozen until hormone assays were performed. All experiments were carried out between times 0900 and 1200.
Intraventricular testing. A chronic, indwelling cannula was implanted in the 3V of -male rats as described with slight modification (16, 17) . One week later a jugular-atrial cannula was implanted (15) . Again, 24 hr later, extension cannulae were attached, and the rats were left undisturbed for 1 hr.
After removal of the zero-time blood sample (0.6 ml), 2 A.l of saline alone or an equal volume of saline containing 15, 30, or 60 pmol of synthetic galanin was injected into the 3V.
In another group of rats, 3 jul of rabbit galanin antiserum (RAS-7153N, Peninsula Laboratories) or normal rabbit serum (NRS) was microinjected into the 3V. Blood samples (0.6 ml) were removed at 5, 15, 30, and 60 min or 1, 2, 3, and 4 hr after the 3V injections. The galanin antiserum had no crossreactivity to secretin, PTIM-27, or vasoactive intestinal polypeptide in RIA (personal communication, G. Chang of Peninsula Laboratories).
Cell Dispersion. Anterior pituitaries removed from male rats after decapitation were minced into small pieces with a razor blade and then dispersed enzymatically by using a solution of 0.1% trypsin (1:250; Difco, Detroit) in minimal essential medium without calcium (GIBCO) containing 0.1% bovine serum albumin (18) .
After 2 hr, the cells were collected by centrifugation and resuspended in medium 199 containing 10% (vol/vol) horse serum and 20 mM Hepes (GIBCO). The medium was adjusted to pH 7.2-7.4 with 0.1 M NaOH. The medium also contained 100 units of penicillin and 100 1Lg of streptomycin per ml. Cells were counted, placed in 12 x 75 mm culture tubes at 5 x 105 cells per tube and cultured overnight at 370C under an air atmosphere.
The following day, the overnight culture medium was removed, and the cells were resuspended in 1 ml of medium 199 containing 0.1% bovine serum albumin for preincubation for 30 min (37QC) in a Dubnoff metabolic shaker. After removal of preincubation medium, the cells were resuspended in 1 ml of medium 199 plus 0.1% bovine serum albumin alone or in 1 ml of a similar medium containing synthetic porcine galanin at final concentrations of 1 nM to 1 /LM. Cells were incubated alone or in combination with various concentrations of galanin with or without 2.5 nM GH-releasing hormone (GRH), 30 nM somatostatin [somatotropin (growth hormone) release-inhibiting hormone, GRIH in Fig. 5] , or 70 or 140 nM TSH-releasing hormone (TRH). All peptides were purchased from Peninsula Laboratories. After incubation for 1 hr at 370C, the cells were pelleted by centrifugation at 250C for 10 min at 500 x g. The media were stored frozen at -200C until measurement of hormone content.
Hormone Assays. PRL, TSH, and GH levels in plasma samples and incubation media were determined by RIA as recommended by the National Institute of Diabetes and 
RESULTS
In Vivo. Low doses of galanin (15, 30 , or 60 pmol) corresponding to 50, 100, and 200 ,g, respectively, were injected into the 3V of freely moving male rats, and plasma GH, PRL, and TSH levels were determined. All doses of galanin increased plasma GH levels significantly at 5, 15, and 30 min after injection. The increases were dose-related, with the two higher doses (30 and 60 pmol) being equally effective at both 5 (P < 0.01) and 15 (P < 0.001) min after injection (Fig.  1) . Plasma PRL levels increased slightly after the injection of 30 and 60 pmol of galanin. However, only the 60-pmol dose of galanin increased plasma PRL levels significantly (Fig. 1) . Statistically, galanin decreased plasma TSH levels only at the 60-pmol dose at 30 and 60 min (Table 1) .
In a second experiment 30 (100 ng) or 300 (1000 ng) pmol of galanin were injected i.v. Galanin (30 pmol) increased plasma GH levels significantly (P < 0.05) by 5 min as compared with values in saline-injected controls (Fig. 2) . Plasma levels of GH after injection of 300 pmol of the peptide were highly significantly increased at 5 min postinjection (P < 0.01) when compared with plasma GH levels in either saline-injected controls or the preinjection levels (Fig. 2) . The response to this dose given i.v. was less than that to a dose lower by a factor of 20 administered intraventricularly. At this concentration of galanin (300 pmol)-injected i.v., no alterations of the plasma levels of PRL and TSH were measured at any sampling time.
Passive immunoneutralization of endogenous galanin by 3V injection of 3 pl of rabbit antiserum to galanin resulted in a rapid 80% decrease of plasma GH levels (Fig. 3) . Plasma levels of GH in the galanin antiserum-injected group decreased abruptly by 15 min postinjection (P < 0.01), while plasma levels of GH in the NRS (3 1.l) -injected groups remained stable. The low plasma GH levels persisted for the 5-hr duration of the experiment (P < 0.001). After 3V injection of galanin antiserum, an increase of plasma levels of TSH was found at 30 and 60 min (P < 0.05 and P < 0.02, respectively (Fig. 4) . By 2 hr, however, TSH values were similar to control TSH levels. Thereafter, TSH levels from anti-galanin antiserum-injected rats showed no significant alteration in comparison with those of NRSinjected controls.
In Vitro. In five separate cell preparations, 1 nM to 1 kLM galanin failed to alter significantly GH, PRL, or TSH release (Figs. 5-7) . However, cells from each preparation did respond to GRH or TRH by releasing significantly greater amounts of GH (Fig. 5) or PRL and TSH than did cells incubated only in control medium (Figs. 6 and 7) . When 100 nM galanin was combined with 70 nM TRH in the incubation medium, TRH-stimulated TSH release was potentiated (P < 0.02). Galanin did not alter significantly the effect of the higher concentration of 140 nM TRH on TSH release (Fig. 6) . The same dose of galanin also potentiated TRH-stimulated PRL release at both TRH concentrations (P < 0.05 and P < 0.02, respectively) (Fig. 7) . In contrast, galanin failed to alter the stimulatory effect of GRH on GH release or the inhibitory effect of somatostatin (Fig. 5) .
DISCUSSION
The present results confirm our earlier finding (13) that intraventricular injection of galanin has a powerful, concentration-dependent stimulatory effect on GH release at very low doses (<15 pmol). Furthermore, galanin is more effective when administered via the intraventricular rather than the i.v. route. Since galanin had no effect on basal, stimulated, or inhibited GH release from anterior pituitary cells in vitro, it is apparent that its primary action is on the hypothalamus. The action of galanin to stimulate GH release appears to be of physiological significance because intraventricular jnjection of highly specific antiserum directed against the peptide produced a' dramatic lowering of plasma GH that was apparent'within 15 (14) reported that passive immunization with specific anti-vasoactive intestinal peptide rabbit serum suppressed the plasma PRL response to galanin (500 pmol; administered to lateral ventricle) in anesthetized rats. In unanesthetized animals, intraventricular injection of antigalanin antiserum failed to alter plasma PRL levels. Therefore, it would appear that galanin plays no significant role in control of basal PRL release; however it will be important to repeat these experiments under conditions of stimulated PRL release to determine whether or not galanin might have a role in the secretion of PRL during periods of stress or suckling.
Although galanin had a suppressive effect on TSH release in vivo only at the 60-pmol dose, the antiserum against galanin increased plasma TSH levels transiently. Since galanin augmented the stimulatory effect of TRH on TSH release but only at 30 nM and not at 140 nM TRH, the in vivo effects of galanin and anti-galanin must be mediated within the hypothalamus, presumably by altering TRH release. Since 140 nM TRH represents nearly a maximal stimulus for in vitro TSH secretion (20) , perhaps the ability of galanin to potentiate TRH-stimulated TSH could not be observed. Since galanin antiserum only produced a transient elevation in plasma TSH concentrations, the physiological significance of galanin in the regulation of TSH secretion remains to be established.
Recently, estrogen has been shown to stimulate dramatically galanin mRNA and galanin synthesis in the anterior pituitary of female rats and to increase circulating galanin (21) . Therefore, it should be important to evaluate the actions of galanin and their physiological significance in normal female animals and those treated with estrogen.
